AUSTIN, Texas—Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:), recently sold a significant portion of his holdings in the company. The sale comes as Natera’s stock has shown remarkable strength, with a 159% return over the past year and the company achieving a market capitalization of $22.12 billion. According to a filing with the Securities and Exchange Commission, Moshkevich sold a total of 24,861 shares of Natera’s common stock on January 22, 2025, generating approximately $4.1 million. These transactions occurred at prices ranging from $164.95 to $171.95 per share.
Following these sales, Moshkevich retains ownership of 140,684 shares in the company. According to the filing, the sales were conducted to satisfy tax withholding obligations related to the vesting of restricted stock units, in accordance with a pre-established trading plan. InvestingPro analysis shows Natera maintains a strong…
